EBE Welcomes the Second Innovative Medicines Initiative – A message from Roberto Gradnik

11 Jul 2014

(Brussels, 11 July 2014)

Dear all,

I had the pleasure of attending this weeks launch event of, the Innovative Medicines Initiative (IMI)2 and delighted to share with you the good news about the world’s biggest public-private partnership in the life sciences entering its second phase with a €3.3 billion budget for the period of 2014-2024, and its ambitious goal of fast-tracking the development of the next generation of medicines, especially in areas where there is an unmet medical or societal need. More importantly The IMI 2 Strategic Research Agenda, which draws heavily on the World Health Organization (WHO) report ‘Priority Medicines for Europe and the World’, will also place a greater emphasis on speeding up patient access to new medicines. IMI is a public-private partnership (PPP) between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The IMI 2 programme will build on the successes of IMI’s first phase (2008-2013 budget of €2 billion), which has delivered breakthroughs in areas as diverse as diabetes, autism, and medicines safety, and will expand the partnership to all players in the health ecosystem.

In terms of both budget and scope, IMI tackles some of the biggest challenges in medical research and drug development, where no single organisation, company or country could do it alone. This time IMI also allows other sectors to join collaborative research projects.

Since 2009, 46 public-private consortia launched for a total budget of €1.6 billion and continues to deliver breakthroughs that are having an impact on drug research and development and, ultimately, patients’ lives. Projects are delivering among others: a better understanding of the underlying causes of disease, new potential targets for drugs, new potential medicines and facilities to support medicines development and new business opportunities for SMEs.

IMI is evolving, with a stronger focus on the needs of patients and society and certainly in the area of personalised medicines. This time IMI offers simpler, more attractive rules and procedures and certainly to become a true applicable tool for micro, small and medium sized biopharmaceutical companies in Europe, allowing even medicines development to take place.

Here are some of the more exciting facts on how IMI2 can help all participating companies:

  • Funding rates and reporting rules aligned with Horizon 2020
  • 100% reimbursement of direct costs for research actions plus 25% flat rate for overhead/indirect cost
  • Protection for beneficiaries under H2020 Guarantee Fund
  • Funding for all non-profit organisations (not just research-based organisations)
  • Funding for companies with annual turnover of up to €500 million and to all non – profit organisations, supporting EBE’s request.
  • Protection for beneficiaries for under H2020 Guarantee Fund
  • Companies from other industries (e.g. biomedical imaging, medical information technology, diagnostics, animal health) can contribute in kind (so contributions matched by IMI funding)
  • IMI2’s flexible intellectual property (IP) policy that ensures all partners’ interests are respected and can be adapted on case by case basis for any project, and also offering incentives to participate.

The first Call of IMI2 is launched this week! With the funding cap elevated to €500 million as suggested by EBE members is now incorporated in the IMI2 rules. EBE intends to play a more active role in steering IMI together with EFPIA and will participate to the operational funding in a limited way. So, I strongly encourage all members now to use the opportunities IMI2 will bring.

Below I also include some links to more information about IMI2.

Best regards,

Roberto Gradnik,
President of EBE

More Information

Video introducing the Innovative Medicines Initiative

Prezi Presentation Detailing IMI Achievements

IMI2 Strategic Research Agenda

IMI Website

IMI calls for topics (link to the process)

About IMI:

About IMI 
The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. 
IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI has a budget of €3.3 billion for the period 2014-2024. Half of this comes from the EU. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects ‘in kind’, for example by donating their researchers’ time or providing access to research facilities or resources. 
More info on IMI: Follow IMI on Twitter: @IMI_JU

About EBE:

European Biopharmaceutical Enterprises, EBE, is the European Trade Association representing the biopharmaceutical companies of all sizes. EBE is a specialised group of EFPIA, European Federation of Pharmaceutical Industries and Associations, and acts as Europe’s expert voice for emerging bioscience & technology and leading platform for health innovation ecosystems. EBE brings together 50 European biopharmaceutical companies and works together with multiple key stakeholders.  More: Twitter: EBE_EU

2017-09-14T13:39:20+00:00July 11, 2014|